Acinetobacter baumannii has emerged in the last decades ... Other therapeutic options include sulbactam, aminoglycosides, polymixyns and tigecycline. The discovery of new therapies coupled with ...

Since tigecycline can be one of the rare treatment options in some multidrug-resistant Gram-negative bacteria (e.g. Acinetobacter baumannii), further studies with higher doses of tigecycline are ...

The clinical burden of carbapenem-resistant Acinetobacter baumannii has worsened across U.S. hospitals in recent years, according to a study published April 17 in BMC Infectious Diseases.

A new modelling study reveals that only 7% of carbapenem-resistant Gram-negative (CRGN) bacterial infections in eight LMICs ...

The sales volume of the antibiotics such as colistin, ceftazidime-avibactam, ceftolozane-tazobactam, polymyxin B, and tigecycline against CRGN bacteria was also considered. A total of 478,790 CRGN ...

The most-procured antibiotic was tigecycline -- usually prescribed in hospitals for serious infections. Most of the 15 lakh infections were found to have occurred in South Asia, with over 10 lakh ...

Even with more restrictive assumptions, the analysis still showed a substantial treatment gap, with only 14.2% of patients ...

A study published April 17 by BMC Infectious Diseases found increased incidents of Acinetobacter baumannii and carbapenem-resistant A. baumannii infections between 2018 to 2022. A. baumannii is a ...

Introduction: Acinetobacter baumannii exhibits high genomic plasticity, enabling it to acquire virulence factors and antibiotic resistance (AR). Understanding its evolutionary adaptations is crucial ...